Literature DB >> 12900744

Noncardiac findings on dual-isotope myocardial perfusion SPECT.

Kim A Williams1, Kalisha A Hill, Candace M Sheridan.   

Abstract

BACKGROUND: This study examined the frequency of reporting noncardiac findings (NCFs), such as malignancies from inspection of raw projection images with dual-isotope single photon emission computed tomography (SPECT) perfusion imaging, which could potentially be of greater clinical importance than myocardial perfusion imaging alone. Dual-isotope (ie, rest thallium 201 and stress technetium 99m sestamibi [MIBI] or Tc-99m tetrofosmin [TET]) SPECT myocardial perfusion imaging combines multipotential tracers for noncardiac purposes (Tl-201 for renal or splenic imaging, inflammation, or lymphoma and MIBI or TET for hepatobiliary imaging and detecting increased mitochondrial number or activity in neoplastic processes). These images are optimally interpreted with cinematic inspection of the raw projection data, but this may not be practiced uniformly in every laboratory. METHODS AND
RESULTS: We reviewed 12,526 computer-generated text reports of dual-isotope perfusion SPECT studies from a 6-year period for NCFs. NCFs were categorized by organ and by probability of malignancy: high (eg, focal breast or lung uptake of MIBI or TET), intermediate (eg, lymph node uptake or thyroid abnormalities), or low (eg, filling defects in liver, kidney, spleen, or gall bladder; ascites; or pleural effusions). Confirmatory imaging studies or clinical confirmation for each NCF was sought. There were a total of 207 NCFs identified in 180 reports (1.7% of reports, ranging from 0% to 2.8% of reports of individual interpreters). Of these, 107 NCFs were unsuspected before SPECT; 24% were considered at high probability for malignancy, and 24% were considered intermediate in likelihood of malignancy. Follow-up data were available for 178 NCFs, confirming 88% of these findings, including 82% of breast foci, 62% of lung foci, 86% of hepatobiliary/spleen abnormalities, and 94% of renal abnormalities. The probability of malignancy was highest (82%) in breast or lung foci in which uptake of both Tl-201 and the Tc-99m-labeled agent was present.
CONCLUSIONS: In patients referred for evaluation of myocardial perfusion, NCFs are unusual and require systematic and careful inspection of projection images for their detection. With Tl-201, TET, MIBI, or dual-isotope imaging, detecting and reporting NCFs may occasionally result in life-saving early cancer identification.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12900744     DOI: 10.1016/s1071-3581(03)00524-5

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  40 in total

1.  Benign versus malignant breast disease: comparison of contrast-enhanced MR imaging and Tc-99m tetrofosmin scintimammography.

Authors:  H M Fenlon; N C Phelan; P O'Sullivan; S Tierney; T Gorey; J T Ennis
Journal:  Radiology       Date:  1997-10       Impact factor: 11.105

2.  201Tl SPECT as an indicator for early prediction of therapeutic effects in patients with non-small cell lung cancer.

Authors:  K Suga; N Kume; K Nishigauchi; N Ogasawara; A Hara; G Miura; T Matsumoto; N Matsunaga
Journal:  Ann Nucl Med       Date:  1998-12       Impact factor: 2.668

3.  Esophageal cancer detection with Tc-99m tetrofosmin SPECT.

Authors:  N Watanabe; T Hirano; Y Fukushima; M Yukihiro; K Aoyagi; K Tomiyoshi; T Inoue; K Endo
Journal:  Clin Nucl Med       Date:  1997-06       Impact factor: 7.794

Review 4.  99m-Tc-tetrofosmin scintigraphy and breast cancer.

Authors:  P Berghammer; R Obwegeser; S Mülauer-Ertl; G Karanikas; C Wiltschke; E Kubista; H Sinzinger; C Zielinski
Journal:  Gynecol Oncol       Date:  1999-04       Impact factor: 5.482

5.  Incremental prognostic value of adenosine stress myocardial perfusion single-photon emission computed tomography and impact on subsequent management in patients with or suspected of having myocardial ischemia.

Authors:  R Hachamovitch; D S Berman; H Kiat; I Cohen; H Lewin; A Amanullah; X Kang; J Friedman; G A Diamond
Journal:  Am J Cardiol       Date:  1997-08-15       Impact factor: 2.778

6.  Effective risk stratification using exercise myocardial perfusion SPECT in women: gender-related differences in prognostic nuclear testing.

Authors:  R Hachamovitch; D S Berman; H Kiat; C N Bairey; I Cohen; A Cabico; J Friedman; G Germano; K F Van Train; G A Diamond
Journal:  J Am Coll Cardiol       Date:  1996-07       Impact factor: 24.094

7.  Evaluation of chemotherapy response in patients with small cell lung cancer using Technetium-99m-tetrofosmin.

Authors:  C H Kao; Y J Ho; Y Y Shen; J K Lee
Journal:  Anticancer Res       Date:  1999 May-Jun       Impact factor: 2.480

Review 8.  The role of 99mTc-sestamibi and other conventional radiopharmaceuticals in breast cancer diagnosis.

Authors:  R Taillefer
Journal:  Semin Nucl Med       Date:  1999-01       Impact factor: 4.446

9.  Separate acquisition rest thallium-201/stress technetium-99m sestamibi dual-isotope myocardial perfusion single-photon emission computed tomography: a clinical validation study.

Authors:  D S Berman; H Kiat; J D Friedman; F P Wang; K van Train; L Matzer; J Maddahi; G Germano
Journal:  J Am Coll Cardiol       Date:  1993-11-01       Impact factor: 24.094

10.  Technetium-99m-sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement.

Authors:  R Taillefer; A Robidoux; R Lambert; S Turpin; J Laperrière
Journal:  J Nucl Med       Date:  1995-10       Impact factor: 10.057

View more
  33 in total

1.  Correct identification of a myocardial perfusion SPECT lesion leads to early diagnosis of lung cancer.

Authors:  Suresh Viswanathan; Jan Mueller-Brand; Matthias E Pfister; Michael J Zellweger
Journal:  J Nucl Cardiol       Date:  2004 May-Jun       Impact factor: 5.952

2.  Myocardial perfusion imaging in a patient with chest pain.

Authors:  Gurusher S Panjrath; Kalyani Narra; Diwakar Jain
Journal:  J Nucl Cardiol       Date:  2004 Jul-Aug       Impact factor: 5.952

3.  Diagnostic value of myocardial SPECT to detect in-stent restenosis after drug-eluting stent implantation.

Authors:  Hyo Eun Park; Bon-Kwon Koo; Kyung-Woo Park; Jin Chul Paeng; Hae-Young Lee; Hyun-Jae Kang; Hyo-Soo Kim
Journal:  Int J Cardiovasc Imaging       Date:  2012-03-07       Impact factor: 2.357

4.  Focal breast uptake of 99mTc-sestamibi in a man with spindle cell lipoma.

Authors:  H Malek; T Ghaedian; N Yaghoobi; F Rastgou; A Bitarafan-Rajabi; H Firoozabadi
Journal:  J Nucl Cardiol       Date:  2012-06       Impact factor: 5.952

5.  Unusual incidental findings by SPECT myocardial perfusion imaging and CT in the same patient.

Authors:  Pradeep Bhambhvani; Eva Dubovsky; Hrudaya Nath; Jaekyeong Heo; Ami Iskandrian
Journal:  J Nucl Cardiol       Date:  2010-10       Impact factor: 5.952

6.  Incidental detection of hepatocellular carcinoma by SPECT myocardial perfusion imaging.

Authors:  Pradeep Bhambhvani; Eva Dubovsky; Jaekyeong Heo; Ami Iskandrian
Journal:  J Nucl Cardiol       Date:  2010-12       Impact factor: 5.952

7.  Demonstration of an ectopic mediastinal parathyroid adenoma on Tc-99m sestamibi myocardial perfusion scintigraphy.

Authors:  Andrei Iagaru; Rory Hachamovitch; Patrick M Colletti; Heidi Wassef
Journal:  J Nucl Cardiol       Date:  2006-09       Impact factor: 5.952

8.  Mimic ascites in a patient undergoing peritoneal dialysis on raw-data image Tc-99m tetrofosmin gated cardiac SPECT.

Authors:  Ching-Yuan Chen; Wei-Jen Shih; Wen-Sheng Huang
Journal:  J Nucl Cardiol       Date:  2005 Mar-Apr       Impact factor: 5.952

9.  Abnormal photopenic area on nuclear perfusion imaging.

Authors:  Muhammad Raza; Mrinalini Meesala; Gurusher Panjrath; Afshin Ghanbarinia; Diwakar Jain
Journal:  J Nucl Cardiol       Date:  2005 Sep-Oct       Impact factor: 5.952

10.  Unusual radiotracer uptake in the lower mediastinum on sestamibi perfusion images.

Authors:  Muhammad Raza; Mrinalini Meesala; Diwakar Jain
Journal:  J Nucl Cardiol       Date:  2005 Nov-Dec       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.